Publications

Peer reviewed publications:

Tabaglio, T., Low, D.H.P., Koon, W.L.T., Goy, P.A., Cywoniuk, P., Wollmann, H., Ho, J., Tan, D., Aw, J., Pavesi, A., Sobczak, K., Wee, D.K.B., Guccione, E.
MBNL1 alternative splicing isoforms play opposing roles in cancer.
Life Sci. Alliance (2018) 1, e201800157.

Georgilis, A., Klotz, S., Hanley, J.H., Herranz, N., Weirich, B., Morancho, B., Leote, A.C., D'Artista, L., Gallage, S., Seehawer, M., Carroll, T., Dharmalingam, G., Wee, K.B., Mellone, M., Pombo, J., Heide, D., Guccione, E., Arribas, J., Barbosa-Morais, N.L., Heikenwalder, M., Thomas, G.J., Zender, L., Gil, J.
PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-Tumorigenic Effects of Senescent Cells.
Cancer Cell (2018) 34, 85-102.

Do, D.V., Strauss, B., Cukuroglu, E., Macaulay, I., Wee, K.B., Hu, T.X., Igor, R.D.L.M., Lee, C., Harrison, A., Butler, R., Dietmann, S., Ule, J., Marioni, J., Smith, C., Göke, J., Surani, M.A.
SRSF3 maintains transcriptome integrity in oocytes by regulation of alternative splicing and transposable elements.
Cell Discovery (2018) 4, 33.

Lin, J., Lee, J.H.J., Paramasivam, K., Pathak, E., Wang, Z., Pramono, Z.A.D., Lim, B., Wee, K.B.*, Surana, U.*
Induced-Decay of Glycine Decarboxylase Transcripts as an Anticancer Therapeutic Strategy for Non-Small-Cell Lung Carcinoma.
Mol. Ther.: Nucleic Acids (2017) 9, 263–273.

Toh, C.X., Chan, J.W., Chong, Z.S., Farran, C.A.E., Wang, H.F., Guo, H.C., Ma, D., Satapathy, S., Goh, G.Y.L., Khattar, E., Yang, L., Tergaonkar, V., Chang, Y.T., Collins, J.J., Daley, G.Q., Wee, K.B., Li, H., Lim, Y.P., Bard, F.A., Loh, Y.H.
RNAi Reveals Phase-Specific Global Regulators of Human Somatic Cell Reprogramming.
Cell Rep. (2016) 15, 2597–2607.

Wee, K.B.*,#, Lee, R.T.C.#, Lin, J., Pramono, Z.A.D., Maurer-Stroh, S.
Discovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous

Heterosubtypic Targeting that Hedge against Antiviral Resistance.
PLoS Comput. Biol. (2016) 12, e1004663.

Koh, C.M., Bezzi, M., Low, D.H.P., Ang, W.X., Teo, S.X., Gay, F.P.H., Al-Haddawi, M., Tan, S.Y., Osato, M., Sabò, A., Amati, B., Wee, K.B., Guccione, E.
MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.
Nature (2015) 523, 96–100.

Pao, P.W., Wee, K.B., Yee, W.C., Pramono, Z.A.D.
Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of *SMN2* gene.
Mol. Ther. (2014) 22, 854–861.

Pramono, Z.A.[#], Wee, K.B.[#], Wang, J.L., Chen, Y.J., Xiong, Q.B., Lai, P.S., Yee, W.C.
A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in DMD gene.
Hum. Gene Ther. (2012) 23, 781–790.

Wee, K.B.*, Yio, W.K., Surana, U., Chiam, K.H.
Transcription factor oscillations induce differential gene expressions.
Biophys. J. (2012) 102, 2413–2423.

Wee, K.B., Surana, U., Aguda, B.D.
Oscillations of the p53-Akt network: implications on cell survival and death.
PLoS One (2009) 4, e4407.

Wee, K.B., Pramono, Z.A., Wang, J.L., MacDorman, K.F., Lai, P.S., Yee, W.C.
Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.
PLoS One (2008) 3, e1844.

Wee, K.B., Aguda, B.D.
Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death.
Biophys. J. (2006) 91, 857–865.

Goryachev, A.B., Toh, D.J., Wee, K.B., Lee, T., Zhang, H.B., Zhang, L.H.
Transition to quorum sensing in an Agrobacterium population: A stochastic model.
PLoS Comput. Biol. (2005) 1, e37.

Patents filed:

Wee, K.B.
Method For Screening Splicing Variants Or Events.
WO 2019/032054 A1.

Guccione, E., Wee, K.B., Bertoletti, A.
Modifying T lymphocytes function with Antisense Oligonucelotides (ASOs) for personalized immune therapy.
SG Patent Application No.: 10201705285S.
Exclusive licensed on 14 Sep 2018.

Surana, U., Wee, K.B., Lin, J., Lim, B.
Steric hindrance antisense oligonucleotides (shAONs) targeting glycine decarboxylase (GLDC) expression as drug candidates for non-small cell lung carcinoma (NSCLC) and other cancers.
SG Patent Application No.: 10201609048R.

Guccione, E., Wee, K.B.
Method of Treating Cancer by Antisense Oligonucleotide Targeting PRDM15.
WO 2018/044239.

Pramono, Z.A., Yee, W.C., Lai, P.S., Wee, K.B.
Antisense oligonucleotides and uses thereof.
WO 2011/078,797.

Trade-secrets lodged:

Wee, K.B.
Methods for the rational design of highly efficacious steric hindrance antisense oligonucleotides (stAONs) for the specific modulations of RNA.
IHPC/Z/09979 (2017).

Wee, K.B., Pramono, Z.A., Lee, R.T.C., Surana, U., Yio, W.K., Maurer-Stroh, S..
An Integrated High-Throughput Technology Platform for the Systematic Selection of Exon Targets and for the Rational Design of Efficacious Antisense Oligonucleotides in Exon Splicing Modulation.
IHPC/Z/07462 (2012).

Wee, K.B., Pramono, Z.A., Yee, W.C.
Methodology for the rational design of efficient AONs to induce specific exon skipping.
IHPC/Z/06180 (2010).

Wee, K.B., Pramono, Z.A., Lee, R.T.C.
Enabling platform for AON target identification and guided-design of efficient AON molecules for disease therapy and biological research.
IHPC/Z/06065 (2010).